Polycystic Liver Disease (PLD) Panel
Use
This test is intended for individuals with a clinical or suspected diagnosis of polycystic liver disease (PLD). It is particularly useful for individuals exhibiting early or atypical renal imaging findings suggestive of PLD, as well as those with sporadic PLD without a known family history. Additionally, it assists in the differential diagnosis of hepatic manifestations between ADPLD, ADPKD, and ARPKD.
Special Instructions
Not provided.
Limitations
This test has not been cleared or approved by the US Food and Drug Administration. Performance and accuracy are subject to the adherence to CAP and CLIA regulations under which the test was developed and validated. Interpretation of variants relies heavily on the completeness and quality of clinical information provided.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided